Τρίτη 2 Ιανουαρίου 2018

PulmCrit- Angiotensin II: five cautions & three comparisons

efficacy23.gif?resize=1000%2C439&ssl=1

Upon first reading the ATHOS-3 trial, I was pleasantly optimistic. Who wouldn't be interested in a shiny new vasopressor? The trial didn't prove much, but it was intriguing. However, it was alarming to hear that the FDA has approved angiotensin II for use based on it. Precious little evidence is available about this drug. With angiotensin II arriving at hospitals soon, some cautions are in order.

EMCrit Project by Josh Farkas.



from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2Cb63d7

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις